Economic evaluation of low-dose SKA cytokines in patients with rheumatoid arthritis in maintaining low disease activity or remission
DOI:
https://doi.org/10.33393/abtpn.2020.2153Keywords:
low-dose SKA cytokines, rheumatoid arthritis, Cost, maintenance, Italian NHSAbstract
Introduction. The administration of low-dose SKA cytokines allows to maintain remission or low disease activity in patients with rheumatoid arthritis. This analysis aims to estimate the maintenance treatment cost of low-dose SKA cytokines versus DMARDs in patients with rheumatoid arthritis.
Methods and Results. Rather than evaluating the cost-effectiveness of individual therapeutic agents, it becomes recommendable for decision-makers to identify an optimal sequencing of such agents. A one-year cost consequence analysis (CCA) was conducted, comparing two alternative strategies to maintain remission or low disease activity in patients with rheumatoid arthritis: i) first line with low-dose SKA cytokines and second line with antitumor necrosis factor-α (TNF-α), ii) first line with DMARDs and second line with TNF-α. The CCA was conducted from the perspective of the Italian National Health Service (iNHS). Only direct medical costs (drugs cost) were considered. We performed a sensitivity analysis to test the robustness of the results. The sequence using cytokines in first line showed the lower mean annual cost of treatment: the mean annual cost per patient was €1,280.96 with cytokines and €1,987.21 with DMARDs. Sensitivity analyses confirmed the base case result.
Conclusion. From the iNHS’s perspective low-dose, SKA cytokines, as first line treatment appears a cost-saving strategy to maintain remission or low disease activity in patients with rheumatoid arthritis. (HTA & Market Access)
Downloads
References
Gibofsky A. Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: A Synopsis. Am J Manag Care. 2014 May;20(7 Suppl):S128-35.
Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care. 2012 Dec;18(13 Suppl):S295-302.
Rossini M, Rossi E, Bernardi D et al. Prevalence and incidence of rheumatoid arthritis in Italy. Rheumatol Int. 2014;34:659-64. Doi: 10.1007/s00296-014-2974-6.
Nell VP, Machold KP, Ebrel G et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology. 2004;43:906-14.
Emery P, Breedveld FC, Dougados M et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence-based development of a clinical guide. Ann Rheum Dis. 2002;61:290-7.
Kuek A, Hazleman BL, Östor AJK. Immune mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83:251-60.
Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001:358:903-11.
Caporali R, Conti F, Alivernini S et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clin Exp Rheumatol. 2011;29(Suppl. 66):S7-S14.
Thwaites C, Finney A. Rheumatoid arthritis. 2: Exploring treatment options to achieve early control and remission. Nurs Times. 2010;106(10):18-20.
National Institute for Health and Clinical Excellence. Rheumatoid arthritis (CG79): full guideline. London, UK: NICE; 2009. http://guidance.nice.org.uk/CG79/Guidance.
Strehblow C, Haberhauer G, Fasching P. Comparison of different biologic agents in patients with rheumatoid arthritis after failure of the first biologic therapy. Wien Med Wochenschr. 2010;160(9-10):225-9.
Burska A, Boissinot M, Ponchel F. Cytokines as biomarkers in rheumatoid arthritis. Mediators Inflamm. 2014;2014:545493.
Venkatesha SH, Dudics S, Acharya B, Moudgil KD. Cytokine-modulating strategies and newer cytokine targets for arthritis therapy. Int J Mol Sci. 2015;16(1):887-906.
Migliore A, Ballanti E, Laganà B et al. Biologic agents for rheumatoid arthritis: can we hypothesize new strategies of treatment? Med Hypotheses. 2014;82(1):117-21.
Martin-Martin LS, Giovannangeli F, Bizzi E et al. An open randomized active-controlled clinical trial with low-dose SKA cytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis. Drug Design, Development and Therapy. 2017;11:985-94.
Markusse IM, Dirven L, Gerards AH et al. Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study. Arthritis Res Ther. 2015;17:232. https://doi.org/10.1186/s13075-015-0730-2
Russell LB, Gold MR, Siegel JE et al. The role of cost-effectiveness analysis in health and medicine. JAMA. 1996;276:1172-7.
Aletaha D, Neogi T, Silman AJ et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580-8.
Adalimumab. Riassunto delle Caratteristiche del Prodotto. Accesso: Aprile 2020. https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_it.pdf
Etanercept. Riassunto delle Caratteristiche del prodotto. Accesso: Aprile 2020. https://www.ema.europa.eu/en/documents/product-information/enbrel-epar-product-information_it.pdf
Infliximab. Riassunto delle Caratteristiche del Prodotto. Accesso: Aprile 2020. https://www.ema.europa.eu/en/documents/product-information/remicade-epar-product-information_it.pdf
Certolizumab. Riassunto delle Caratteristiche del Prodotto. Accesso: Aprile 2020. https://www.ema.europa.eu/en/documents/product-information/cimzia-epar-product-information_it.pdf
Golimumab. Riassunto delle Caratteristiche del Prodotto. Accesso: Aprile 2020. https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_it.pdf
Lista di trasparenza. Accesso: Aprile 2020. https://www.aifa.gov.it/pt/liste-di-trasparenza
Abatacept. Riassunto delle Caratteristiche del Prodotto. Accesso: Aprile 2020. https://www.ema.europa.eu/en/documents/product-information/orencia-epar-product-information_it.pdf
Tocilizumab. Riassunto delle Caratteristiche del Prodotto. Accesso: Aprile 2020. https://www.ema.europa.eu/en/documents/product-information/roactemra-epar-product-information_it.pdf
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2020 Roberto Ravasio, Alberto Migliore
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors contributing to AboutOpen agree to publish their articles under the Creative Commons NonCommercial 4.0 International License (CC BY-NC 4.0), which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.
Accepted 2020-07-01
Published 2020-09-01
